

Press release from Emotra AB (publ)

Göteborg, May 15, 2019

Communiqué from the Annual General Meeting of EMOTRA AB (publ)

The Annual General Meeting of EMOTRA AB (publ) was held today, May 15, 2019. The resolutions, summarised below, were all adopted with the necessary majority.

Net income appropriation

The AGM approved the Board's proposal for allocation of the Company's loss as presented in the annual report. Furthermore, the Board recommends no dividend be paid for the financial year 2018. The AGM also granted the Board of Directors and the CEO discharge for the financial year 2018.

Determination of the number of board members and deputy members, as well as the number of accountants and deputy accountants; Determination of the fees to be paid to the board members and accountant

The AGM decided that the Board shall be composed of four regular members and no deputy members and set the annual compensation for the Board to 162,750 SEK, whereof 69,750 SEK for the chairperson (1.5 x the price basic amount) and 46,500 SEK (1 price basic amount) each for the two external/independent regular board members. Furthermore, the AGM decided that an auditor and a deputy auditor shall be appointed, and that they shall be compensated in line with usual charges and upon presentation of approved invoice.

Election of Board of Directors and accountant

The AGM decided that Claes Holmberg, Jan Pilebjer* and Lars-Håkan Thorell shall be re-elected as regular board members. Furthermore the AGM resolved to re-elect Anna Sjörs* as regular board member to replace the resigning board member Margit Ferm. Furthermore, the AGM passed a resolution to renew the appointment of Thomas Nilsson as the Company's auditor and Marcus Hellsten as deputy auditor until the end of next year's Annual General Meeting.

** independent board members, according to the regulatory framework of Spotlight Stockmarket*

Anna Sjörs Dahlman, born in 1981, PhD in medicine, specialising in rehab medicine. Anna has a background in Engineering Biology, specialising in Medical Engineering, and has performed research on measuring physiological reactions to short-term and long-term stress, pain, sleep deprivation, physical activity, etc. Much of this research was performed at the Institute of Stress Medicine in Göteborg. Anna has also worked as a guest researcher at the Naval Postgraduate School in Monterey, USA. Her research there concerned the biological effects of shift work and disturbed sleep. She is a member of the board of directors of the Swedish Society of Behavioural Medicine since 2013. Anna has gained experience and knowledge of electrodermal measurements through her own research and previous co-operation with Lars-Håkan Thorell, and possesses a considerable understanding of the EDOR test. Today, Anna is a researcher at the Swedish National Road and Transport Research Institute where she studies fatigue detection and physiological monitoring of drivers.

Resolution on amendment of the Articles of Association (item 12)

The AGM passed a resolution on the following amendments of the Articles of Association:

<i>Former wording</i>	<i>New wording</i>
§ 4 Share capital The share capital shall amount to a minimum of 1,760,804.10 SEK and a maximum of 7,043,216.40 SEK.	§ 4 Share capital The share capital shall amount to a minimum of 500,000 SEK and a maximum of 2,000,000 SEK.
§ 5 Number of shares The number of outstanding shares shall be at least 9,517,860 and at most 38,071,440.	§ 5 Number of shares The number of outstanding shares shall be at least 26,315,789 and at most 105,263,156.

Resolution to reduce the share capital (item 13)

The Board resolved to reduce the Company's share capital by 4,380,699.994 SEK through an allocation to the non-restricted equity. This reduction will be carried out without decreasing the number of outstanding shares. After the reduction, the quota value will be 0.019 SEK.

This reduction requires approval by the Swedish Companies Registration Office (Bolagsverket) as well as an amendment of the Company's articles of association.

Resolution authorising the Board to issue new shares (item 14)

The AGM resolved to authorise the Board to issue new shares, within the framework of the Swedish articles of association, on one or more occasions up until the next AGM, with or without deviation from the shareholders' preferential rights. The number of shares issued under the authorisation shall correspond to a maximum amount of 2.5 million euro (total issue proceeds).

The shares will be issued at a market-equivalent price, minus a market-rate issue rebate, when appropriate, and payment can, in addition to cash, be made in kind or as otherwise conditioned.

The goal of any new share issue that is decided based on the granted authority shall be to reinforce the Company's working capital to finance the market launch of the Company's method EDOR®.

If the Board decides on a new issue deviating from the shareholders' preferential rights, the reason should be diversification of ownership.

EMOTRA AB (publ)
THE BOARD OF DIRECTORS



Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company's method, EDOR[®], is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.

Emotra AB (publ), Göteborgsvägen 88, SE-433 63 Sävedalen, Sweden
Tel: +46 732 34 41 93, www.emotra.se